Jeremy Grantham Arcus Biosciences, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $600,100 - $1.14 Million	-35,300 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $778,156 - $1.16 Million	-45,400 Reduced 56.26%	35,300 $605,000
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $1.13 Million - $2.95 Million	80,700 New	80,700 $2 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.